SG11201407397WA - Formulations and methods for vaginal delivery of antiprogestins - Google Patents
Formulations and methods for vaginal delivery of antiprogestinsInfo
- Publication number
- SG11201407397WA SG11201407397WA SG11201407397WA SG11201407397WA SG11201407397WA SG 11201407397W A SG11201407397W A SG 11201407397WA SG 11201407397W A SG11201407397W A SG 11201407397WA SG 11201407397W A SG11201407397W A SG 11201407397WA SG 11201407397W A SG11201407397W A SG 11201407397WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- antiprogestins
- woodlands
- rule
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 5 December 2013 (05.12.2013) WIPOIPCT (10) International Publication Number WO 2013/181449 A1 (51) International Patent Classification: A61K 9/00 (2006.01) A61K 9/48 (2006.01) (21) International Application Number: PCT/US2013/043447 (22) International Filing Date: 30 May 2013 (30.05.2013) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 61/653,674 31 May 2012 (31.05.2012) US (71) Applicant: REPROS THERAPEUTICS INC. [US/US]; 2408 Timberloch Place, Suite B-7, The Woodlands, TX 77380 (US). (72) Inventors: PODOLSKI, Joseph, S.; 3 Pebble Hollow Court, The Woodlands, TX 77381 (US). HSU, Kuang; 71 N. Misty Morning Trace, The Woodlands, TX 77381 (US). (74) Agents: CLOUGH, David, W. et al.; Morgan, Lewis & Bockius LLP, Attention: Docketing Department, 1111 Pennsylvania Avenue, N.W., Washington, DC 20004 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) (54) Title: FORMULATIONS AND METHODS FOR VAGINAL DELIVERY OF ANTIPROGESTINS Figure 1 Observed AUC of Combined Parent and Metabolite 3000 2500 2000 0\ T-H 00 I t Imgoral 3mgoral Bmgoral 9mgoral 12mgora! 12mgVaginal (57) Abstract: The subject matter of the present invention is pertinent to the field of vaginal delivery of pharmaceutically active © agents. Embodiments of the instant invention disclose methods for treating variety a of progesterone related disorders by vaginal ad- CJ ministration of pullulan a capsule comprising one or more antiprogestins.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261653674P | 2012-05-31 | 2012-05-31 | |
| PCT/US2013/043447 WO2013181449A1 (en) | 2012-05-31 | 2013-05-30 | Formulations and methods for vaginal delivery of antiprogestins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407397WA true SG11201407397WA (en) | 2014-12-30 |
Family
ID=48614182
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201704858PA SG10201704858PA (en) | 2012-05-31 | 2013-05-30 | Formulations and methods for vaginal delivery of antiprogestins |
| SG11201407397WA SG11201407397WA (en) | 2012-05-31 | 2013-05-30 | Formulations and methods for vaginal delivery of antiprogestins |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201704858PA SG10201704858PA (en) | 2012-05-31 | 2013-05-30 | Formulations and methods for vaginal delivery of antiprogestins |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10328022B2 (en) |
| EP (1) | EP2854763B1 (en) |
| JP (1) | JP6341910B2 (en) |
| KR (1) | KR102127348B1 (en) |
| CN (1) | CN104334158B (en) |
| AU (1) | AU2013267359C1 (en) |
| BR (1) | BR112014029131B1 (en) |
| CA (1) | CA2872644A1 (en) |
| CL (1) | CL2014003232A1 (en) |
| CO (1) | CO7141411A2 (en) |
| CR (1) | CR20140567A (en) |
| EA (1) | EA030444B1 (en) |
| ES (1) | ES2701400T3 (en) |
| HK (1) | HK1206622A1 (en) |
| IL (1) | IL235450B (en) |
| IN (1) | IN2014DN10548A (en) |
| MX (2) | MX363640B (en) |
| NZ (1) | NZ702467A (en) |
| PH (1) | PH12014502516B1 (en) |
| SG (2) | SG10201704858PA (en) |
| UA (1) | UA114106C2 (en) |
| WO (1) | WO2013181449A1 (en) |
| ZA (1) | ZA201408262B (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3936133A1 (en) | 2011-11-23 | 2022-01-12 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10064815B2 (en) | 2014-05-05 | 2018-09-04 | Repros Therapeutics Inc. | Formulations and methods for vaginal delivery of antiprogestins |
| KR20170005819A (en) | 2014-05-22 | 2017-01-16 | 쎄러퓨틱스엠디, 인코퍼레이티드 | Natural combination hormone replacement formulations and therapies |
| US11623008B2 (en) * | 2014-08-20 | 2023-04-11 | Professional Compounding Centers Of America | Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan |
| JP2017531026A (en) * | 2014-10-20 | 2017-10-19 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド | Sustained release abuse deterrent liquid filler form |
| EP3025709B1 (en) | 2014-11-27 | 2020-09-30 | Capsugel Belgium NV | Dosage form articles for external mucosal applications |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| AU2017239645A1 (en) | 2016-04-01 | 2018-10-18 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| AU2018251256B2 (en) * | 2017-04-14 | 2023-10-05 | Capsugel Belgium Nv | Pullulan capsules |
| AU2018253392B2 (en) | 2017-04-14 | 2023-11-02 | Capsugel Belgium Nv | Process for making pullulan |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2377418A1 (en) | 1977-01-13 | 1978-08-11 | Roussel Uclaf | NEW 4,9-DIENIC 11B-SUBSTITUTE STEROID DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICINAL PRODUCTS |
| FR2521565B1 (en) | 1982-02-17 | 1985-07-05 | Dior Sa Parfums Christian | PULVERULENT MIXTURE OF LIPID COMPONENTS AND HYDROPHOBIC CONSTITUENTS, METHOD FOR PREPARING SAME, HYDRATED LIPID LAMELLAR PHASES AND MANUFACTURING METHOD, PHARMACEUTICAL OR COSMETIC COMPOSITIONS COMPRISING HYDRATED LAMID PHASES |
| FR2522328B1 (en) | 1982-03-01 | 1986-02-14 | Roussel Uclaf | NEW PRODUCTS DERIVED FROM THE STRUCTURE 3-CETO 4,9 19-NOR STEROIDS, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS |
| FR2534487B1 (en) | 1982-10-15 | 1988-06-10 | Dior Christian Parfums | METHOD FOR THE HOMOGENEIZATION OF HYDRATED LIPIDAL LAMELLAR PHASE DISPERSIONS, AND SUSPENSIONS OBTAINED THEREBY |
| DE3237814A1 (en) * | 1982-10-12 | 1984-04-12 | Warner-Lambert Co., 07950 Morris Plains, N.J. | WATER-FREE EMULSIONS AND USE THEREOF |
| AU565354B2 (en) | 1983-11-14 | 1987-09-10 | Bio-Mimetics Inc. | Bioadhesive compositions and methods of treatment therewith |
| FR2598421B1 (en) | 1986-05-06 | 1988-08-19 | Roussel Uclaf | NOVEL 19-NOR OR 19-NOR D-HOMO STEROIDS SUBSTITUTED IN POSITION 11B BY A RADICAL PHENYL CARRYING AN ALKYNYL RADICAL, THEIR PREPARATION METHOD, THEIR APPLICATION AS MEDICAMENTS AND THE COMPOSITIONS CONTAINING THEM |
| US4954490A (en) | 1988-06-23 | 1990-09-04 | Research Triangle Institute | 11 β-substituted progesterone analogs |
| US5077211A (en) | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
| US5468741A (en) | 1993-05-28 | 1995-11-21 | The Regents Of The University Of California | Use of low levels of mifepristone to treat leiomyomata |
| US5543150A (en) | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
| IL112778A0 (en) * | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| DE4426601A1 (en) | 1994-07-27 | 1996-02-01 | Schering Ag | Use of a combination product containing a competitive progesterone antagonist and a progestogen for the manufacture of a medicament for the treatment of endometriosis or Leiomyomata uteri |
| AU714959B2 (en) | 1995-02-02 | 2000-01-13 | Schering Aktiengesellschaft | Progesterone antagonists for the production of pharmaceutical agents for the treatment of dysfunctional uterine bleeding |
| GB9522403D0 (en) * | 1995-11-01 | 1996-01-03 | Hoechst Roussel Ltd | Intravaginal drug delivery device |
| US6900193B1 (en) | 1996-05-01 | 2005-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
| ES2152671T3 (en) | 1996-05-01 | 2001-02-01 | Us Gov Health & Human Serv | PROGESTERONE DERIVATIVES REPLACED IN POSITION 21 AS NEW ANTIPROGESTATIONAL AGENTS. |
| AU2805397A (en) | 1996-08-30 | 1998-03-19 | Population Council, Center For Biomedical Research, The | Vaginal application mifepristone |
| US6682174B2 (en) | 1998-03-25 | 2004-01-27 | Silverbrook Research Pty Ltd | Ink jet nozzle arrangement configuration |
| US20050070516A1 (en) | 1997-10-28 | 2005-03-31 | Vivus Inc. | As-needed administration of an androgenic agent to enhance female desire and responsiveness |
| US6020328A (en) | 1998-03-06 | 2000-02-01 | Research Triangle Institute | 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| EP1008443A1 (en) | 1998-12-08 | 2000-06-14 | Alusuisse Technology & Management AG | Sterilisable multilayer film for packaging |
| US6740645B1 (en) | 1999-09-03 | 2004-05-25 | Research Triangle Institute | 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties |
| AR025609A1 (en) * | 1999-09-13 | 2002-12-04 | Hoffmann La Roche | SOLID LIPID FORMULATIONS |
| UA74168C2 (en) | 1999-10-05 | 2005-11-15 | Коламбіа Леборетеріс (Бермуда) Лімітед | Use of beta-adrenergic agonist for treating endometriosis and infertility as well as for improving fertility |
| ATE396197T1 (en) | 2000-03-17 | 2008-06-15 | Us Gov Health & Human Serv | 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE WITH ANTIGESTAGENIC ACTIVITY |
| IN191020B (en) | 2000-03-28 | 2003-09-13 | Dabur Res Foundation | |
| IL154975A0 (en) | 2000-10-18 | 2003-10-31 | Schering Ag | Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases |
| WO2003005954A2 (en) | 2001-07-09 | 2003-01-23 | Zonagen, Inc. | Methods and materials for the treatment of testosterone deficiency in men |
| EP1427366A2 (en) | 2001-08-29 | 2004-06-16 | UMD, Inc. | Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy |
| JP2003143474A (en) | 2001-11-02 | 2003-05-16 | Matsushita Electric Ind Co Ltd | Image signal processing system |
| US7417013B2 (en) | 2002-05-01 | 2008-08-26 | Mcneil-Ppc, Inc. | Warming and nonirritating lubricant compositions and method of comparing irritation |
| CA2523859C (en) | 2003-04-29 | 2011-08-02 | The General Hospital Corporation | Methods and devices for the sustained release of multiple drugs |
| EP1593376A1 (en) | 2004-05-04 | 2005-11-09 | Warner-Lambert Company LLC | Improved pullulan capsules |
| DE602005026290D1 (en) | 2004-07-09 | 2011-03-24 | Population Council Inc | COMPOSITIONS OF DELAYED RELEASE WITH PROGESTERONE RECEPTOR MODULATORS |
| GT200500185A (en) | 2004-08-09 | 2006-04-10 | PROGESTERONE RECEIVER MODULATORS UNDERSTANDING PIRROL-OXINDOL DERIVATIVES AND THEIR USES | |
| EP1865938A4 (en) | 2005-03-22 | 2008-09-24 | Repros Therapeutics Inc | Dosing regimes for trans-clomiphene |
| JP2008536910A (en) | 2005-04-20 | 2008-09-11 | ファイザー・リミテッド | Pyrazole derivatives as progesterone receptor antagonists |
| DE102005030294A1 (en) | 2005-06-24 | 2007-01-04 | Schering Ag | Nonsteroidal progesterone receptor modulators |
| CN101316595A (en) * | 2005-09-29 | 2008-12-03 | 利普生物药剂公司 | Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride |
| CN1846703A (en) | 2006-02-13 | 2006-10-18 | 程定超 | Vagina administration mifepristone prepn and its composition and prepn process |
| WO2007103510A2 (en) | 2006-03-08 | 2007-09-13 | Danco Laboratories Llc | Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders |
| JP2008012281A (en) * | 2006-06-05 | 2008-01-24 | Koritsu Shoji:Kk | Insertion assisting device |
| KR20070116538A (en) * | 2006-06-05 | 2007-12-10 | 유겐가이샤 코리츠 쇼지 | Insertion supporting implement |
| CZ300424B6 (en) * | 2006-06-20 | 2009-05-13 | Pliva - Lachema A. S. | Pharmaceutical composition for peroral administration |
| HUE036870T2 (en) | 2006-10-24 | 2018-08-28 | Repros Therapeutics Inc | Compositions and methods for suppressing endometrial proliferation |
| EP2144601A4 (en) * | 2007-04-05 | 2012-10-10 | Univ Kansas | Rapidly dissolving pharmaceutical compositions comprising pullulan |
| ES2575554T3 (en) | 2007-04-20 | 2016-06-29 | Preglem S.A. | Selective progesterone modulators in the treatment of uterine hemorrhage |
| WO2009037704A1 (en) | 2007-09-20 | 2009-03-26 | Bio-Pro Medical Ltd. | Compositions and means for treating uterine leiomyomata, leiomyoma, myoma, uterine fibroids, endrometriosis, adenomyosis and related disorders by mifepristone |
| TWI477276B (en) | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | Antiprogestin dosing regimens |
| EP2482914A1 (en) * | 2009-09-29 | 2012-08-08 | Koninklijke Philips Electronics N.V. | Intrauterine electronic capsule for administering a substance |
| UA113283C2 (en) | 2010-12-23 | 2017-01-10 | 19-NORSTEROIDS AND THEIR APPLICATIONS FOR THE TREATMENT OF PROGESTERON-STAINLESS STATES | |
| DE202011110355U1 (en) | 2011-03-09 | 2014-01-15 | Arstat, Inc. | Treatment of uterine fibroids by intravaginal administration of a low dose of a selective progesterone receptor modulator, an antigestagens or an antigestagen agent |
| UA113291C2 (en) | 2011-08-04 | 2017-01-10 | TRANSCLOMYPHENE METABOLITES AND THEIR APPLICATIONS |
-
2013
- 2013-05-30 WO PCT/US2013/043447 patent/WO2013181449A1/en active Application Filing
- 2013-05-30 UA UAA201414106A patent/UA114106C2/en unknown
- 2013-05-30 ES ES13728632T patent/ES2701400T3/en active Active
- 2013-05-30 IN IN10548DEN2014 patent/IN2014DN10548A/en unknown
- 2013-05-30 CA CA2872644A patent/CA2872644A1/en not_active Abandoned
- 2013-05-30 NZ NZ702467A patent/NZ702467A/en not_active IP Right Cessation
- 2013-05-30 SG SG10201704858PA patent/SG10201704858PA/en unknown
- 2013-05-30 MX MX2014014054A patent/MX363640B/en unknown
- 2013-05-30 EP EP13728632.4A patent/EP2854763B1/en active Active
- 2013-05-30 KR KR1020147032210A patent/KR102127348B1/en active IP Right Grant
- 2013-05-30 CN CN201380028413.4A patent/CN104334158B/en not_active Expired - Fee Related
- 2013-05-30 AU AU2013267359A patent/AU2013267359C1/en not_active Ceased
- 2013-05-30 US US14/403,141 patent/US10328022B2/en not_active Expired - Fee Related
- 2013-05-30 EA EA201492290A patent/EA030444B1/en unknown
- 2013-05-30 JP JP2015515205A patent/JP6341910B2/en not_active Expired - Fee Related
- 2013-05-30 BR BR112014029131-4A patent/BR112014029131B1/en not_active IP Right Cessation
- 2013-05-30 SG SG11201407397WA patent/SG11201407397WA/en unknown
-
2014
- 2014-11-02 IL IL235450A patent/IL235450B/en active IP Right Grant
- 2014-11-11 ZA ZA2014/08262A patent/ZA201408262B/en unknown
- 2014-11-11 PH PH12014502516A patent/PH12014502516B1/en unknown
- 2014-11-19 MX MX2019003467A patent/MX2019003467A/en unknown
- 2014-11-25 CO CO14259346A patent/CO7141411A2/en unknown
- 2014-11-27 CL CL2014003232A patent/CL2014003232A1/en unknown
- 2014-12-09 CR CR20140567A patent/CR20140567A/en unknown
-
2015
- 2015-07-30 HK HK15107275.4A patent/HK1206622A1/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407397WA (en) | Formulations and methods for vaginal delivery of antiprogestins | |
| SG11201408174UA (en) | Antibody formulation | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201811549UA (en) | Boronic acid derivatives and therapeutic uses thereof | |
| SG11201408646VA (en) | Dimeric protein with triple mutations | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
| SG11201407340YA (en) | Treatment of myelosuppression | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201407200TA (en) | Liquid formulation | |
| SG11201407961WA (en) | Risperidone or paliperidone implant formulation | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201811580SA (en) | Compositions, devices, and methods for the treatment of alcohol use disorder | |
| SG11201902531QA (en) | Liquid pharmaceutical composition | |
| SG11201408292YA (en) | Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same | |
| SG11201408509PA (en) | Racecadotril lipid compositions | |
| SG11201809788VA (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
| SG11201408262XA (en) | Temperature stable vaccine formulations | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders |